What is the core difference between Mounjaro and Ozempic?
Mounjaro and Ozempic are both incretin-based injectables approved for type 2 diabetes, but they activate a different number of receptors. Ozempic, whose active molecule is semaglutide, is a single agonist: it activates the GLP-1 receptor. Mounjaro, whose active molecule is tirzepatide, is a dual agonist — it activates the GLP-1 receptor and adds a second target, the GIP receptor.
That second receptor is the headline difference. GIP (glucose-dependent insulinotropic polypeptide) is a separate incretin hormone, and engaging its receptor alongside GLP-1 is the mechanistic rationale for the larger blood-sugar and weight effects tirzepatide produced when the two drugs were compared directly. A single-receptor drug and a dual-receptor drug are pulling on a different number of metabolic levers.
The regulatory picture, by contrast, is symmetric. Both are FDA-approved for type 2 diabetes — Ozempic since 2017, Mounjaro since 2022 — so unlike many comparisons in this class, neither one is investigational. The difference is in mechanism and in the comparative evidence, not in whether a clinician can prescribe them.
Which controls blood sugar better, Mounjaro or Ozempic?
These two were compared head-to-head, which is rare in this drug class and makes the answer unusually direct. In the SURPASS-2 trial, both drugs were added to metformin in adults with type 2 diabetes and followed for 40 weeks, with tirzepatide tested at 5, 10, and 15 mg against semaglutide at 1 mg.
Tirzepatide lowered HbA1c more at every dose. The reductions were −2.01, −2.24, and −2.30 percentage points for tirzepatide 5, 10, and 15 mg, versus −1.86 percentage points for semaglutide 1 mg, with all comparisons reaching statistical significance (P<0.001). In plain terms, the dual agonist moved the primary diabetes marker further than the single agonist in the same trial.
The mechanistic interpretation is the one above: tirzepatide's second incretin receptor, GIP, is the rationale for the greater HbA1c reduction. Worth noting is that SURPASS-2 compared tirzepatide against the 1 mg dose of semaglutide — the highest Ozempic dose studied in that trial — not against the 2 mg dose that the label later allowed.
How do Mounjaro and Ozempic compare on weight?
Weight change was a secondary outcome in SURPASS-2, and there too the dual agonist came out ahead. Across the three tirzepatide doses, the body-weight treatment difference versus semaglutide 1 mg was −1.9, −3.6, and −5.5 kg, all favoring tirzepatide and all statistically significant.
The gap widened with dose: the 15 mg arm of tirzepatide separated from semaglutide 1 mg by 5.5 kg, while the 5 mg arm separated by 1.9 kg. The pattern is consistent with the HbA1c result — the more of the dual agonist, the larger the difference from the single agonist on the same metric.
One framing caveat matters here. SURPASS-2 was a type 2 diabetes trial, and these weight figures describe the difference between the two drugs in that population. They are not a weight-management indication, and they should be read as comparative trial data, not as a target for any individual.
What is the cardiovascular evidence for each?
Cardiovascular outcomes are where the evidence base is currently asymmetric, and it favors Ozempic. In the SUSTAIN-6 trial in people with type 2 diabetes, semaglutide reduced major adverse cardiovascular events, with a hazard ratio of 0.74 versus placebo. That is a dedicated outcomes trial reporting a reduction in cardiovascular events, not a surrogate marker.
Mounjaro does not yet have an equivalent result. Its dedicated cardiovascular-outcomes trial is ongoing, so there is no comparable hazard ratio to report for tirzepatide at this time. This is a difference in the maturity of the evidence, not a finding that tirzepatide is worse on cardiovascular endpoints — that question simply has not reported yet.
The reason this matters in clinic is that cardiovascular benefit is a distinct decision input from glycemic or weight effect. A patient with established cardiovascular risk and a clinician weighing outcomes data have a documented result on the Ozempic side and a pending trial on the Mounjaro side.
It is worth being precise about what the SUSTAIN-6 hazard ratio of 0.74 means and does not mean. It describes semaglutide's effect on cardiovascular events in a type 2 diabetes population in that specific trial — a comparative result against placebo, not against tirzepatide. The two drugs have not been compared on cardiovascular endpoints head-to-head, and the absence of a tirzepatide outcomes figure is a gap in the data, not a measured difference. Until the tirzepatide trial reports, the honest statement is that one drug has a published cardiovascular-outcomes result and the other does not yet.
How are Mounjaro and Ozempic dosed and titrated?
Both are once-weekly subcutaneous injections, and both follow the same titrate-slowly principle: start low to limit gastrointestinal side effects, then step up. The starting doses are introductory and are not intended to be therapeutic targets.
Per the FDA label, Ozempic (semaglutide) for type 2 diabetes starts at 0.25 mg once weekly for four weeks — an initiation dose, not a treatment dose — then increases to 0.5 mg, can step up to 1 mg, and can go up to 2 mg once weekly. Mounjaro (tirzepatide) starts at 2.5 mg once weekly for four weeks, then increases by 2.5 mg increments no sooner than every four weeks, with maintenance doses of 5, 10, or 15 mg and a maximum of 15 mg once weekly.
The structures rhyme: a four-week introductory dose on each drug, then stepwise escalation a clinician controls. The figures here are label information, not a recommendation — the right dose, and whether to titrate at all, is a decision for the prescriber who knows the patient's history.
How do the side effects of Mounjaro and Ozempic compare?
The side-effect profiles look broadly similar, which is expected because both drugs share GLP-1 receptor activity. The dominant adverse events for both are gastrointestinal — nausea, diarrhea, vomiting, and constipation — and for both they are dose-dependent and tend to ease as the body adapts to gradual dose escalation.
That shared profile is also why both labels build in a low introductory dose and a slow titration schedule. The four-week starting dose on each drug exists to blunt the early gastrointestinal effects rather than to drive the therapeutic result, and side effects that appear at one step often settle before the next increase.
Because the two drugs share a mechanism on the GLP-1 arm, side-effect management follows the same logic for both: titrate gradually, give the body time to adapt, and keep the prescribing clinician informed of anything that does not settle. The specifics of how to manage any reaction belong with that clinician.
One practical implication for tracking: because the gastrointestinal effects are dose-dependent on both drugs, they tend to cluster around each dose step rather than appearing at random. Logging when a side effect started relative to the last increase gives a clinician the signal they need to decide whether to hold a dose, slow the titration, or proceed. That is the same monitoring discipline for either molecule, which is convenient if a patient ever transitions between them under a clinician's direction.
Which one is right for you?
For someone deciding today, both are legitimate, approved options for type 2 diabetes, so the decision turns on which evidence input weighs most. On glycemic control and weight, the head-to-head SURPASS-2 data favored tirzepatide over semaglutide 1 mg. On cardiovascular outcomes, semaglutide has a reported reduction in major adverse cardiovascular events (SUSTAIN-6), while tirzepatide's outcomes trial is still ongoing.
Those are not the same kind of fact, and they do not collapse into a single ranking. Greater HbA1c and weight effect in one trial, and a documented cardiovascular-outcomes result in another, are separate considerations that a clinician weighs against a specific patient's history, comorbidities, and goals.
This decision belongs with a licensed clinician who can read those inputs against your individual situation. Nothing here is medical advice or an endorsement of either drug — it is a comparison of what the trials and labels report.
Tracking either compound on PeptidePanel
Whichever drug a clinician prescribes, the day-to-day work is the same: log doses, watch the biomarkers that matter (HbA1c, weight trend, lipids, blood pressure), and catch side effects early. PeptidePanel is the neutral tracking layer for that — it records the protocol your clinician sets, charts your bloodwork against reference ranges, and reminds you when a dose or a lab is due.
PeptidePanel does not sell, source, or supply any compound. It is a monitoring tool for protocols that a qualified prescriber has put you on.